Tirofiban Combined with Fondaparinux for Post-PCI Treatment of Patients with Acute Coronary Syndrome and Mild Renal Insufficiency

Abstract

Proper administration of antithrombotic and antiplatelet drugs after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) and renal insufficiency is a challenging task. In this study, we utilized Fondaparinux and Tirofiban (either separately or combined) to treat post-PCI patients with ACS and concurrent renal insufficiency. The patients were followed-up for 1 year. We observed that combined treatment led to a higher number of significant therapeutic effects and better reduced the frequency of bleeding events. Our findings indicate that combined antithrombotic and antiplatelet treatment improves the prognosis in patients with ACS and renal insufficiency who received PCI treatment.

Relationship between lncRNA-Ang362 and prognosis of patients with coronary heart disease after percutaneous coronary intervention

“…At present, coronary artery revascularization mainly includes coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) [ 8 ]. With the advent of PCI, its rapid development and the continuous emergence of new anticoagulant and antiplatelet drugs has continuously broken through the restricted area of PCI treatment [ 9 ]. Nevertheless, the severity and complexity evaluation of coronary artery disease (CAD) in CHD patients require objective and accurate indexes.…”